Repeated need for tranquillisation ‐ not reported · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes repeated need for tranquillisation compared with COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE (very low certainty).
1 finding from 1 review
Aggression · psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in specific behaviours ‐ aggression compared with COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE (moderate certainty).
1 finding from 1 review
Global outcomes · psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in global outcomes compared with COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE (moderate certainty).
1 finding from 1 review
Adverse effects: specific ‐ acute dystonia · psychosis‐induced aggression or agitation
HALOPERIDOL may leads to higher adverse effects: specific ‐ acute dystonia compared with COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE (low certainty).
1 finding from 1 review
Adverse effects: specific ‐ seizure · psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in adverse effects: specific ‐ seizure compared with COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE (low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · nonmetastatic esophageal cancer
Chemoradiotherapy showed no clear difference in overall survival compared with chemoradiotherapy plus surgery (high certainty).
1 finding from 1 review
Freedom from locoregional relapse · nonmetastatic esophageal cancer
Chemoradiotherapy probably leads to lower freedom from locoregional relapse compared with chemoradiotherapy plus surgery (moderate certainty).
1 finding from 1 review
Quality of life · nonmetastatic esophageal cancer
1 finding from 1 review
Treatment‐related mortality · nonmetastatic esophageal cancer
Chemoradiotherapy may leads to higher treatment‐related mortality compared with chemoradiotherapy plus surgery (low certainty).
1 finding from 1 review
Use of salvage procedures for dysphagia · nonmetastatic esophageal cancer
Chemoradiotherapy may leads to lower use of salvage procedures for dysphagia compared with chemoradiotherapy plus surgery (low certainty).
1 finding from 1 review
Failure to maintain remission · Patients with quiescent ulcerative colitis
It is very uncertain whether 6‐Mercaptopurine changes failure to maintain remission compared with methotrexate (very low certainty).
1 finding from 1 review
Clinical remission1 · Patients with active Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in clinical remission1 compared with methotrexate (low certainty).
1 finding from 1 review
Adverse events · Patients with active Crohn's disease
Azathioprine or 6‐mercaptopurine may leads to lower adverse events compared with methotrexate (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
It is very uncertain whether azathioprine or 6‐mercaptopurine changes withdrawals due to adverse events compared with methotrexate (very low certainty).
1 finding from 1 review
Participants with severe withdrawal · People undergoing managed opioid withdrawal
Alpha2‐adrenergic agonist showed no clear difference in participants with severe withdrawal compared with methadone (low certainty).
1 finding from 1 review
Peak withdrawal score · People undergoing managed opioid withdrawal
1 finding from 1 review
Overall withdrawal severity · People undergoing managed opioid withdrawal
1 finding from 1 review
Duration of treatment · People undergoing managed opioid withdrawal
1 finding from 1 review
Number experiencing hypotensive or other adverse effects · People undergoing managed opioid withdrawal
Alpha2‐adrenergic agonist may leads to higher number experiencing hypotensive or other adverse effects compared with methadone (low certainty).
1 finding from 1 review